Expanded Access to Mepsevii
Sponsor
Ultragenyx Pharmaceutical Inc (Industry)
Overall Status
Available
CT.gov ID
NCT03775174
Collaborator
(none)
Study Details
Study Description
Brief Summary
Individual patient expanded access requests may be considered for patients who have no other treatment options
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Detailed Description
Expanded access may provide access for treatment prior to approval by the local regulatory agency. For full details, please visit the link provided.
Study Design
Study Type:
Expanded Access
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Ultragenyx Pharmaceutical Inc
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.Responsible Party:
Ultragenyx Pharmaceutical Inc
ClinicalTrials.gov Identifier:
NCT03775174
Other Study ID Numbers:
- UX003-EAP
First Posted:
Dec 13, 2018
Last Update Posted:
May 27, 2022
Last Verified:
May 1, 2022
Keywords provided by Ultragenyx Pharmaceutical Inc
Additional relevant MeSH terms: